Skip to content

Effect of yoga and physical exercises on Telomere length in Diabetes mellitus

Comparative study on Leukocyte Telomere length between yoga and physical exercise among Type 2 Diabetes mellitus- A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027695
Enrollment
148
Registered
2020-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Yoga: Yoga including Asanas Pranayama Meditation will be given Total Duration : 45 minutes 5 days/week for 6 Months Control Intervention1: Physical Exercises: Brisk Walking Control

Sponsors

Department of Science and Technology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of diabetes in accordance with American Diabetic Association criteria (fasting plasma glucose >=126mg/dl (>=7.0 mmol/L) OR 2hr Plasma Glucose >=200mg/dl (11.1mmol/L) OR HbA1C >= 6.5% (48mmol/mol) OR Random plasma glucose >=200mg/dl (11.1mmol/L) American Diabetes Association 2016 2. Diagnosed condition of DM2 for 1 to 3 years 3. Subjects on stable glycemic medication for past 3 months 4. Ability and willingness to give consent and comply with study

Exclusion criteria

Exclusion criteria: 1. Subjects with previously diagnosed cardiovascular disease (hypertension, hyperlipidemia, Obesity (>30 wt/metre 2 ), Coronary artery disease, heart failure) 2. Subjects with pregnancy, neurological disorders and cancer 3. Acute and chronic inflammation caused by diseases other than T2DM such as COPD 4. Subjects with history of smoking and alcohol 5. Subjects on exercise intervention, dietary programs or regimens in the last 3 months 6. Subjects with musculoskeletal conditions impairing the performance of any physical activity 7. Subjects with known type 1 diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Leukocyte Telomere LengthTimepoint: Baseline, 3 months and 6 months

Secondary

MeasureTime frame
HbA1CTimepoint: Baseline, 3 months and 6 months;MalondialdehydeTimepoint: Baseline, 3 months and 6 months;Super Oxide DismutaseTimepoint: Baseline, 3 months and 6 months

Countries

India

Contacts

Public ContactDr V Prem

Manipal Academy of Higher Eduacation

prem.v@manipal.edu9886647732

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026